XF-73
 | |
| Identifiers | |
|---|---|
718638-68-7  | |
| 3D model (Jmol) | Interactive image |
| ChemSpider | 8094227 |
| PubChem | 9918582 |
| |
| |
| Properties | |
| C44H50Cl2N6O2 | |
| Molar mass | 765.82 g·mol−1 |
| Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa). | |
| Infobox references | |
XF-73 (Exeporfinium chloride) is an experimental drug candidate. It is an anti-microbial that works via weakening bacteria cell walls.[1] It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.[2][3][4]
Structurally it is a dicationic porphyrin.[5]
It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.[1][6]
In 2014 a phase 1 clinical trial for nasal administration was run.[7]
As of February 2016 another phase 1 clinical trial (for nasal administration) is recruiting.[8]
References
- 1 2 Neka Sehgal (20 September 2010). "Promising new drug XF-73 kills superbugs within 5 minutes". Archived from the original on 21 July 2011.
- ↑ "XF-73". Destiny Pharma. (Shows molecular structure.)
- ↑ Miller, K.; Ooi, N.; Hobbs, J. K.; Rhys-Williams, W.; Love, W. G.; Hayter, I.; Katila, M.; Chopra, I. (19 April 2008). "XF-73, a novel anti-staphylococcal antimicrobial with very rapid bactericidal activity". European Society of Clinical Microbiology and Infectious Diseases.
- ↑ Mary Dejevsky (18 May 2008). "Scientists 'on brink of cure' for superbug". The Independent.
- ↑ "XF series". Destiny Pharma.
- ↑ Tom Chivers (18 May 2008). "MRSA: UK scientists 'close to a treatment". The Daily Telegraph.
- ↑ Study of the Nasal Decolonisation of Staphylococcus Aureus (SA) and the Safety and Tolerability of XF-73 Nasal Gel in Healthy Subjects
- ↑ Study of the Safety and Local Tolerability of Intranasal Gel Formulations of XF-73
This article is issued from Wikipedia - version of the 2/28/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.